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Abstract
Gold nanorods (GNRs, ~ 50 × 15 nm) have been used ubiquitously in biomedicine for their optical 
properties, and many methods of GNR biofunctionalization have been described. Recently, the 
synthesis of larger-than-usual GNRs (LGNRs, ~ 100 × 30 nm) has been demonstrated. However, 
LGNRs have not been biofunctionalized and therefore remain absent from biomedical literature to 
date. Here we report the successful biofunctionalization of LGNRs, which produces highly stable 
particles that exhibit a narrow spectral peak (FWHM ~100 nm). We further demonstrated that 
functionalized LGNRs can be used as highly sensitive scattering contrast agents by detecting 
individual LGNRs in clear liquids. Owing to their increased optical cross sections, we found that 
LGNRs exhibited up to 32-fold greater backscattering than conventional GNRs. We leveraged 
these enhanced optical properties to detect LGNRs in the vasculature of live tumor-bearing mice. 
With LGNR contrast enhancement, we were able to visualize tumor blood vessels at depths that 
were otherwise undetectable. We expect that the particles reported herein will enable immediate 
sensitivity improvements in a wide array of biomedical imaging and sensing techniques that rely 
on conventional GNRs.
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Nanoparticles can be synthesized in a vast array of shapes and sizes to suit specific needs in 
biomedical therapy and imaging. Gold Nanorods (GNRs) have been particularly useful 
therapeutic1–6 and imaging contrast agents7–19 ever since protocols for simple GNR 
synthesis were first reported.20–23 These original methods produced GNRs with approximate 
dimensions of 50 × 15 nm. Groups have adapted these GNRs for applications including 
photothermal therapy,1,3,4 two-photon luminescence,7–9 Surface-Enhanced Raman 
Scattering (SERS),109–13 photoacoustic imaging,149–17 and optical coherence tomography 
(OCT).18,19 Recently, methods to produce significantly larger GNRs (up to 150 × 50 nm) 
have been developed.24 Based on theoretical modeling,259–28 these large GNRs (LGNRs) 
are predicted to offer advantages in numerous biomedical imaging techniques due to greater 
absorption and scattering cross sections relative to their commonly used smaller 
counterparts.
Despite their clear advantages, LGNRs have not been utilized in biomedical studies to date. 
The greatest barrier to employing LGNRs in biomedical studies is the need for robust 
surface chemistry to achieve particle stability, nontoxicity, and biofunctionality for targeted 
imaging and therapy. While numerous groups have stabilized GNRs by replacing residual 
cetyltrimethylammonium bromide (CTAB, left over from GNR synthesis) with thiolated 
polyethylene glycol (PEG-SH) reagents3,29 or through polyelectrolyte 
overcoating,1,4,7,10,30–32 no study to date has described surface modifications and biological 
use of LGNRs. Because of their significant size difference, it is unclear whether coating 
methods that work for GNRs will also work for LGNRs. From a practical standpoint, 
functional surface chemistry methods for coating LGNRs must exist to realize their 
advantages as biomedical imaging agents. Furthermore, particles must remain stable 
throughout (i) multiple washing steps to remove cytotoxic surfactants and (ii) conjugation 
reactions with biomolecules of interest.30,31 Thus, a rigorous characterization of LGNR 
stability and surface chemistry must be explored if their optical superiority to conventional 
GNRs is to be leveraged.
To explore whether LGNRs can be successfully adapted for biological studies, we compared 
the stability of GNRs (~50 × 15 nm) and LGNRs (~100 × 30 nm) as a function of surface 
coating. We found that while conventional PEG surface coating stabilized GNRs, it did not 
stabilize LGNRs. We explored this difference in mechanistic detail and found that it arose 
from the nature of the surfactant-directed growth process. To circumvent the instability of 
LGNRs coated with PEG, we used poly(sodium 4-styrenesulfonate) (PSS) to render LGNRs 
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that exhibited excellent colloidal stability. Importantly, we also developed methods to further 
functionalize PSS-coated LGNRs with biological ligands of interest. Finally, we used OCT 
to demonstrate that LGNRs produce much stronger optical signals than GNRs and therefore 
enable vast improvements to imaging sensitivity both in vitro and in vivo.
 2. EXPERIMENTAL SECTION
 Particle Synthesis and Characterization
GNRs and LGNRs were synthesized at two different peak wavelengths each (I: ~ 750 nm 
and II: ~ 800 nm) using protocols described by El-Sayed23 and Murray,24 respectively. 
Particle morphologies and size distributions were characterized from transmission electron 
micrographs acquired with a JEOL TEM 1400. Absorbance measurements for each particle 
type were obtained using a Cary 6000i spectrometer operating in transmission mode from 
400 to 1100 nm.
 Size-Dependent Stability Characterization
(L)GNRs were prepared with one of three surface coatings: CTAB, mPEG-SH (MW ~ 5 
kDa), or PSS (MW ~ 70 kDa), resulting in (L)GNRs-CTAB, (L)GNRs-mPEG, and 
(L)GNRs-PSS, respectively. Coated particles were then washed through multiple rounds of 
centrifugation at 2550g followed by resuspension in distilled deionized (DDI) water. 
Stability trends for (L)GNRs were characterized by changes in spectral bandwidth (a proxy 
for colloidal stability/particle aggregation) as a function of surface coating and the number 
of wash cycles. (L)GNR zeta potentials were also measured using electrophoretic light 
scattering (ELS) after each round of washing. Successful surface coating was verified 
through TEM, Vis-NIR spectrometry, and dynamic light scattering (DLS) characterization 
following particle incubation with PSS or various PEG-SH ligands. Extensive additional 
methods to investigate the mechanisms of size-dependent stability trends are provided and 
discussed in the Supporting Information (SI).
 LGNR Biostability
The stability of LGNRs-PSS in biological environments was also assayed. LGNRs-mPEG 
and LGNRs-PSS were prepared as 1 mL aliquots and incubated with 500 µL Fetal Bovine 
Serum (FBS). As an additional test of LGNR biostability and potential toxicity, LGNRs-
PSS-mPEG were prepared and injected at high doses (up to 80 mg/kg) into female nude 
(nu−/nu−) and C57BL/6 mice. Injected mice were monitored over a period of 3 months for 
signs of distress.
 LGNR Functionalization for Specific Ligand–Receptor Binding
LGNRs-PSS were incubated with either mPEG-SH or Biotin-PEG-SH and washed 2× to 
remove excess reagents (resulting in LGNRs-PSS-mPEG and LGNRs-PSS-PEG-Biotin, 
respectively). LGNRs-PSS-PEG-Biotin and LGNRs-PSS-mPEG were further incubated with 
FBS to simulate biological environments and then mixed with streptavidin-coated 
polystyrene beads in water to assay binding specificity. These incubation conditions were 
repeated with streptavidin-coated beads that were prereacted with excess biotin to confirm 
the molecular specificity of the LGNR binding interaction.
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 Optical Comparison of GNRs vs LGNRs
GNRs and LGNRs were prepared to equal concentrations (2 × 1010 nps/mL) and 
(separately) to equal optical density (OD 1) in glass capillary tubes and scanned using a 
spectral domain optical coherence tomography (SD-OCT) probe. The OCT signal from each 
sample was quantified using region of interest analysis to determine the relative scattering 
intensity of GNRs and LGNRs (see Detailed Experimental Methods in SI). LGNRs were 
also prepared in water at various concentrations ranging from 2 × 108 – 2 × 1010 nps/mL 
(500 fM to 50 pM) to determine imaging sensitivity for LGNR detection.
 LGNR Contrast Enhancement in vivo
LGNRs-PSS-mPEG (250 µL of 23.5 nM, peak wavelength = 804 nm) were injected 
intravenously into a female nude mouse (anesthetized with 1% isoflurane inhalation) bearing 
a U87MG tumor xenograft in the right ear pinna. OCT images were acquired pre- and 
postinjection and compared to assess the presence of LGNR contrast-enhancement in 
healthy and tumor microvasculature.
 3. RESULTS
 Particle Morphology and Spectra
TEM images reveal the significant size differences between GNRs (~50 × 15 nm) and 
LGNRs (~100 × 30 nm) (Figure 1a and SI Figure S1). Interestingly, LGNRs exhibited 
greater monodispersity than GNRs as evidenced by particle size distributions (Figure 1b) 
and spectral bandwidths (Figure 1c).
 Gold Nanorods of Different Sizes Exhibit Unique Stability Trends
It is critical for (L)GNRs to remain stable through multiple washes so that cytotoxic CTAB 
can be removed and the particles can be further functionalized for biological use. As 
expected based on previous reports,30,32 (L)GNRs-CTAB synthesized by either method 
aggregated after minimal washing by centrifugation (Figure 2a–e and Figures S2 and S3). 
LGNRs-CTAB aggregated after two rounds of washing while GNRs-CTAB aggregated after 
three rounds. While GNRs-mPEG remained stable for an additional wash relative to GNRs-
CTAB, LGNRs-mPEG experienced no such increase in stability relative to LGNRs-CTAB. 
This suggested that LGNRs did not benefit from mPEG coating. Unlike LGNRs-mPEG, 
LGNRs-PSS exhibited marked improvements in stability, remaining stable for more than 
four washes. Long-term particle stability (“shelf-life”) is also an important practical 
consideration. We found that LGNRs-PSS stored at 4 °C were stable for more than a year 
(Figure S11).
Zeta potential measurements (Figure 2f and Figure S4, Table S1) indicated a rapid shift from 
positive to negative surface potential for LGNRs-CTAB incubated with PSS, which led to 
increased stability consistent with polyelectrolytic overcoating.31,32 In contrast, the zeta 
potentials of LGNRs-CTAB and LGNRs-mPEG were positive, but tended toward zero as 
observed for GNRs-CTAB and GNRs-mPEG. Despite the similarities in stability and zeta 
potential for LGNRs-CTAB and LGNRs-mPEG, later studies indicated that PEG-SH 
reagents do successfully bind LGNRs to provide particle coating. We did not observe 
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spectral broadening for LGNRs upon addition of PSS or after washing. These findings 
indicated that conventional PEG-based methods for GNR surface coating were insufficient 
to confer stability in aqueous solutions for GNRs of different sizes. However, PSS could be 
used successfully to stabilize LGNRs in water.
We wanted to understand why PEG-SH stabilized GNRs but not LGNRs. Based on previous 
studies of PEG-SH to GNRs,33–37 we hypothesized that the stability difference between 
GNRs and LGNRs arose from the specific locations of PEG-SH binding on the (L)GNR 
surface. Specifically, we expected that those binding sites influenced the extent to which 
PEG can cover the (L)GNR surface. To address these differences, we added mPEG-SH to 
GNRs-CTAB and observed that the particles underwent plasmonic red-shifting (~20 nm), 
and LGNRs-CTAB incubated with PSS exhibited blue-shifting (~10 nm). Both of these 
shifts suggested successful surface modification (Figure S5). While LGNRs-mPEG 
exhibited no significant change in plasmonic resonance relative to LGNRs-CTAB, an 
increase in hydrodynamic diameter of ~10 nm was observed for LGNRs-CTAB following 
mPEG-SH incubation (Table S2), indicating successful mPEG-SH conjugation. Next, we 
sought to explore where PEG-SH reagents bind to (L)GNR surfaces. To study this, LGNRs-
CTAB and GNRs-CTAB were incubated with Biotin-PEG-SH to produce LGNRs-PEG-
Biotin and GNRs-PEG-Biotin, respectively. We then attached 10 nm NeutrAvidin-coated 
gold nanospheres (GNS-NA) to LGNRs-PEG-Biotin (see Supporting Results for more 
details). TEM images showed that GNS-NA localized preferentially to the end-caps of 
LGNRs-PEG-Biotin, but no such pattern was observed when GNS-NA were incubated with 
LGNRs-mPEG (Figure S6). This confirmed our hypothesis that PEG-SH reagents bound 
primarily to the end-caps of (L)GNRs. LGNRs-mPEG incubated with GNS-NA exhibited 
partial aggregation as observed by TEM, spectral broadening, and DLS, indicative of 
instability. However, LGNRs-PEG-Biotin remained stable, and they experienced ~20 nm 
red-shifting and increased hydrodynamic diameter after GNS-NA incubation (Figures S6–7, 
Table S3), consistent with an effective increase in particle aspect ratio due to GNS binding at 
LGNR end-caps (for more information, see Supporting Results).
 Biostability of LGNRs
Absorbance measurements indicated that LGNRs-PSS remained stable during and after 
incubation with FBS followed by washing (Figure 3a, see detailed Experimental Section). 
Interestingly, LGNRs-mPEG incubated with FBS were stable after two washes while 
LGNRs-mPEG in water were stable for only one wash. It is likely that adsorbed FBS (the 
so-called “protein corona”) is responsible for this extended stability. Spectral broadening 
occurred after the third wash for LGNRs-mPEG but not for LGNRs-PSS (Figure 3b,c). This 
result showed that, while LGNRs-mPEG aggregated, LGNRs-PSS remained stable even 
after excess FBS was washed away. Furthermore, we qualitatively observed no adverse 
effects or behavioral changes in female nude (nu−/nu−) and C57BL/6 mice (n = 5) up to 
three months after intravenous administration of LGNRs-PSS-mPEG. These observations 
suggest that, in addition to being biostable, LGNRs-PSS-mPEG can be used safely in animal 
experiments. Ex vivo analysis of resected mouse tissues further indicated the in vivo stability 
of LGNRs-PSS-mPEG (Figure S12).
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 LGNR Functionalization for Specific Ligand–Receptor Binding
Several previous reports describe conjugation of antibodies to GNRs-PSS through 
electrostatic adsorption.1,7,10,31 However, covalent chemistry and high-affinity biomolecule 
interactions are favorable because they are more stable than electrostatic adhesions in 
biological fluids. Furthermore, specific chemistry can be used to bind biomolecules such as 
antibodies at specific functional groups rather than generic electrostatic patches. We 
therefore tested methods to conjugate biological molecules to LGNRs-PSS through specific 
interactions. Because of the high affinity interaction between biotin and streptavidin, we 
hypothesized that LGNRs-PSS-PEG-Biotin would bind to the beads, whereas LGNRs-PSS-
mPEG would remain free in solution (Figure 4a, “Binding Assay”). After 20 s of 
centrifugation at 1000g, a dark red pellet of LGNRs-PSS-PEG-Biotin and streptavidin beads 
was observed, and the color of the supernatant was markedly clear, indicating an absence of 
free LGNRs-PSS-PEG-Biotin in solution. In contrast, the pellet from the LGNRs-PSS-
mPEG incubation was white (the color of beads only) and the supernatant from this 
incubation remained very red, indicating the presence of GNRs in solution (Figure S8a). 
After washing beads postincubation, a clear difference in bead pellet color was observed for 
streptavidin beads incubated with LGNRs-PSS-PEG-Biotin versus LGNRs-PSS-mPEG in 
FBS (Figure S8b). This difference indicated that LGNRs-PSS-PEG-Biotin bound with 
specificity to streptavidin coated beads even in the presence of FBS while LGNRs-PSS-
mPEG do not. Furthermore, blocking the streptavidin-coated beads with free biotin prior to 
GNR incubation (Figure 4a, “Blocking Assay”) prevented LGNRs-PSS-PEG-Biotin binding 
(note the lack of red color in the pellet). The LGNRs-PSS-mPEG result remained the same 
as in the unblocked condition (Figure S8b). To confirm visual assessments of each assay, we 
measured absorbance spectra for supernatants from blocked and unblocked incubation 
conditions. Despite using equivalent amounts of GNRs in each incubation, a much higher 
concentration of LGNRs-PSS-mPEG remained in solution compared to LGNRs-PSS-PEG-
Biotin. This result indicated that more LGNRs-PSS-PEG-Biotin were removed from 
solution (i.e., bound to beads) than LGNRs-PSS-mPEG. However, preincubation of the 
streptavidin beads with free biotin prevented this effect (Figure 4b), suggesting that the 
observed interaction of LGNRs-PSS-PEG-Biotin and streptavidin beads was molecularly 
specific. The results of the binding and blocking assays collectively indicated that 1) PEG-
SH reagents are capable of binding the surface of LGNRs-PSS and 2) heterobifunctional 
PEG molecules (e.g., Biotin-PEG-SH) can be conjugated to LGNRs-PSS to enable 
subsequent specific conjugation with biological ligands of interest, even in the presence of 
nonspecific proteins.
We further explored LGNR bioconjugation by preparing LGNRs-PSS-coated with cyclic 
RGD (cRGD), a peptide that binds with high affinity to αVβ3 integrin, a cell-surface receptor 
overexpressed by numerous cancer cell lines. Dark-field spectral microscopy revealed that 
U87MG cells (which are αVβ3+) exhibited greater uptake of LGNRs targeted with cRGD 
compared to uptake of LGNRs-mPEG or LGNRs functionalized with the low-affinity 
control peptide, cRAD (Figures S13, see Detailed Experimental Methods in Supporting 
Information).
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 Optical Advantages of LGNRs
In addition to developing methods to prepare LGNRs for biological applications, we sought 
to demonstrate the favorable optical properties of LGNRs relative to conventional GNRs. 
LGNRs (2 × 1010 nps/mL) exhibited an intense OCT signal compared to GNRs at the same 
concentration, which were barely distinguishable above the system’s noise threshold (p < 
0.0001; Figure 5a, Figures S9–10). In order to accurately compare the OCT signals of 
LGNRs and GNRs, we also scanned GNRs at an 8-fold higher concentration (1.6 × 1011 
nps/mL), which produce the same optical density (OD) as LGNRs prepared at 2 × 1010 
nps/mL. Even at this 8× higher concentration, the OCT signal of GNRs was only ~¼ that of 
the LGNRs signal (p < 0.0001; Figure 5b), suggesting that LGNRs produce ~32-fold greater 
OCT signal than GNRs per particle. We were also able to detect individual LGNRs with 
OCT, enabling single-particle imaging sensitivity in vitro (Figure 5c). Consistent with 
theoretical predictions, this result suggested that scattering constitutes a greater proportion 
of the total absorbance of LGNRs versus GNRs, making LGNRs an excellent OCT contrast 
agent. Together, the scattering and absorbance measurements indicated that GNRs may be 
replaced with LGNRs in existing biomedical studies for greatly enhanced optical effects.
 LGNR Enhancement of in Vivo Imaging
Contrast sensitivity is critical for observing fine details in biological samples, especially 
deep within intact tissue. We wanted to test whether the strong optical signal from LGNRs 
could improve OCT imaging sensitivity for in vivo studies. Due to scattering and absorption, 
OCT has a limited imaging depth, which typically prevents the detection of fine structures 
more than a few hundred microns into intact tissue. However, IV-administered LGNRs-PSS-
mPEG produced enough backscattering to provide strong contrast enhancement in blood 
vessels, particularly in small vessels (<100 µm in diameter) over 500 µm deep within the 
tumor. In this case, the contrast from LGNRs-PSS-mPEG enabled detection of vasculature at 
twice the depth achievable with OCT alone (Figure 5d).
 4. DISCUSSION
Perhaps the most interesting finding from this study is that GNRs of larger-than-
conventional sizes cannot be sufficiently stabilized by one of the most commonly 
implemented surface modification methods (PEGylation). This result is consistent with 
previous reports that describe a decrease in gold nanosphere stability with increasing 
size.38–40 Our results show that PEG-SH binding occurs mostly at the ends of (L)GNRs, 
which agree with previous reports detailing how nanorod synthesis conditions lead to face-
dependent PEG-SH binding.36–40 Specifically, PEG-SH reagents preferentially bind to the 
end-caps of (L)GNRs while the longitudinal faces remain largely coated with excess CTAB 
from synthesis. CTAB is removed through multiple wash steps, leaving only the (L)GNR 
end-caps protected with a PEG coating. It is interesting to note that the maximum 
outstretched length of PEG-SH reagents with MW ~ 5 kDa is ~50 nm, and the persistence 
length in solution is expected to be ~25 nm.41 This persistence length implies that bundled 
PEG chains anchored by Au–S bonds to both GNR end-caps may still provide stabilization 
to a significant portion of the GNR longitudinal surface. Because LGNRs have greater 
lengths than GNRs, end-bound PEG-SH reagents at persistence length likely do not provide 
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sufficient coating of the longitudinal surface area after CTAB is washed away. This surface 
area exposure may ultimately lead to earlier particle aggregation when compared to GNRs-
mPEG. Unlike PEG-SH, PSS binding to LGNRs-CTAB is not limited to the end-caps. The 
anions in PSS can bind CTAB cationic head groups across the LGNRs-CTAB surface to 
provide a more thorough particle overcoating. Even if CTAB is washed away, the GNR 
surface remains wrapped in the large (~70 kDa) polyanion. Additionally, LGNRs-PSS are 
expected to remain stable in solution due to strong interparticle electrostatic repulsion. This 
repulsion is expected to be more effective than inter-GNR steric hindrance provided by 
PEG-SH (for more information, see Supporting Information). Interestingly, a previous study 
by Mehtala and Wei suggests that small GNRs coated with PSS form minor aggregates that 
are detectable through single-nanoparticle tracking methods (LGNRs were not tested). 
However, the detected aggregates did not produce observable changes to the Vis-NIR spectra 
of GNRs-PSS relative to fully dispersed GNRs.42 The use of PSS to coat the surface of 
extremely long gold nanoparticles (>400 nm) has previously been reported, however the 
biostability and in vivo use of these particles was not evaluated.43 Moreover, particles with 
such extreme high aspect ratios may be unsuitable for live animal applications due to shape-
dependent toxicity and poor cellular uptake (similar to effects observed for carbon 
nanotubes).44,45 Thus, the biofunctionalized LGNRs reported herein alleviate a 
technological gap between small (<50 nm), low-signal particles and exceedingly large (>200 
nm), potentially toxic particles.
LGNRs-PSS are also stable in biological conditions. This is based on our observations that 
LGNRs-PSS incubated with FBS remained highly stable and that intravenous injection of 
LGNRs led to visible increases in OCT contrast (which relies on retention of particle 
spectral properties and thus particle stability). Furthermore, LGNRs-PSS-mPEG caused no 
signs of distress in nude (nu−/nu−) or C57BL/6 mice, indicating that these particles are 
suitable for use in live animals.
A highly advantageous characteristic for any biomedical nanoparticle is the ability to bind 
specific molecular targets of interest. Molecular specificity is enabled by the use of a surface 
coating that can be further conjugated with biological ligands or antibodies. Ideally, 
molecular targeting moieties can be linked to the nanoparticle through covalent bonds or 
high-affinity biomolecular interactions. Our proof of concept binding experiments with 
LGNRs-PSS-PEG-Biotin and streptavidin beads and targeted cell incubation experiments 
show that LGNRs-PSS can be functionalized with such biological ligands. Through this 
demonstration, we have developed LGNRs as a versatile platform for producing molecularly 
targeted contrast agents.
Our comparison of GNR and LGNR OCT signals empirically demonstrates a key benefit of 
LGNRs for future applications in biomedicine. Consistent with theory and simulation,25,26 
LGNRs scatter significantly more light than GNRs, making them ideal agents for scattering-
based imaging modalities. While small GNRs have been demonstrated for OCT contrast 
enhancement,18 the ability to identify individual LGNRs described in this report realizes a 
new level of OCT imaging sensitivity. Spectral domain OCT contrast enhancement can also 
be optimized by selecting LGNRs with a plasmonic peak that overlaps strongly with the 
OCT illumination source and detection range.
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Practical advantages of increased imaging sensitivity from LGNR increased scattering 
include the detection of fine anatomical structures with in vivo OCT imaging. The several 
hundred micron increase in imaging depth enabled by LGNR contrast may offer technical 
improvements for OCT investigations of skin lesions, particularly in distinguishing benign 
from growing malignant tumors through identification of angiogenesis.
Because the total interaction with light is greater for LGNRs than conventional GNRs, we 
expect that LGNRs may enable similar enhancements for other near-infrared imaging 
techniques that use GNRs. Small GNRs-mPEG produced using the Murray method have 
been used for deep-tissue three-photon luminescence imaging in mice.46 The use of LGNRs-
PSS may further improve the achievable sensitivity and depth of luminescence imaging 
techniques owing to greater per particle photon interaction. Surface-enhanced raman 
scattering (SERS) is another imaging technique that commonly relies on GNRs to increase 
the signals of Raman-active dyes. While not in the scope of this report, future SERS 
comparisons of GNR and LGNR signal enhancement may reveal additional biosensing 
application for the functionalized LGNRs reported herein.
 5. CONCLUSION
In summary, this work not only underscores the relation between nanoparticle size and 
stability but also offers immediate improvements to current biological studies that use gold 
nanorod contrast agents. LGNRs are not stabilized by the steric effects through which PEG 
chains improve the stability of GNRs. Unlike GNRs, LGNRs may require stabilization 
through stronger electrostatic repulsive interactions among particles. More importantly, this 
work has demonstrated the practical benefits of understanding LGNR stability. From an 
applications-based standpoint, it is critical to note that LGNRs (and perhaps other types of 
nanoparticles) must be functionalized using tailored surface chemistry methods if their 
advantages in biomedical imaging and therapy are to be realized. In achieving one such 
tailored approach, we have developed improved functionalized nanoparticles that can 
provide immediate enhancements in detection sensitivity for contrast-enhanced imaging and 
biosensing techniques that currently rely on conventional GNRs.
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TEM transmission electron microscopy
Vis-NIR visible-near-infrared
OCT optical coherence tomography
DLS dynamic light scattering
FWHM full width at half-maximum
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Initial particle characterization. (a) TEM images of GNRs (length: 45 ± 7 nm, width: 14 ± 2 
nm) and LGNRs (length: 93 ± 7 nm, width: 33 ± 1 nm) produced by separate methods (scale 
bars = 100 nm). Additional TEM images are provided in Figure S1. (b) Particle aspect ratio 
(AR) distributions for GNR and LGNR batches (n = 80 for each) were determined. GNRs 
AR: 3.3 ± 0.6, and LGNRs AR: 3.0 ± 0.3. (c) Absorbance spectra of each GNR batch were 
also measured. GNRs peak wavelength: 802 nm, and LGNRs peak wavelength: 804 nm. 
LGNRs exhibited a narrower spectrum (FWHM = 100 nm) than GNRs (FWHM = 150 nm).
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Characterization of GNR stability trends as a function of size and surface coating. (a,b) 
GNRs and LGNRs were initially characterized by Vis-NIR spectrometry and Electrophoretic 
Light Scattering (ELS) and subsequently prepared with one of three different surface coating 
molecules. (c) Coated GNRs were then subjected to consecutive rounds of washing with 
distilled deionized water and centrifugation. GNRs were analyzed by Vis-NIR spectrometry 
and ELS after each wash to evaluate particle stability. (d,e) Particle stability was measured 
as spectral peak broadening by dividing the longitudinal absorbance peak full width at half-
maximum before washing (FWHM0) by peak full width at half-maximum after each of the 
washes (FWHMn, where n = 0–3). Plotting FWHM0/FWHMn for each GNR size and 
coating reveals trends in stability for comparison. Original absorbance spectra for all GNRs 
are presented in Figures S2 and S3. (f) Zeta potential measurements for LGNRs are 
consistent with spectral stability trends, and they also provide validation of successful 
surface coating. Error bars represent standard error of the mean (s.e.m.) from triplicate 
measurements. Zeta potential measurements for all GNRs are presented in Figure S4 and 
Table S1.
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LGNRs are robustly stable in biological serum. (a) LGNRs-mPEG and LGNRs-PSS were 
prepared, incubated with fetal bovine serum (FBS) for 3 h, and subjected to three rounds of 
washing by centrifugation. (b) The normalized absorbance spectrum of each GNR type was 
taken after each wash to assess serum stability. Measurements of absorbance peak FWHM0/
FWHMn demonstrate that LGNRs-PSS are more stable in biological serum than LGNRs-
mPEG. (c) Raw absorbance spectra for each particle type demonstrate this difference in 
stability more clearly, as LGNRs-mPEG exhibit virtually no plasmonic peak after the third 
wash. Unlike LGNRs-mPEG, LGNRs-PSS exhibit little change in absorbance properties.
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LGNRs-PSS can be subsequently functionalized to achieve high-specificity molecular 
binding properties. (a) LGNRs-PSS-PEG-Biotin and LGNRs-PSS-mPEG were prepared and 
incubated with FBS to mimic biological environments. FBS-incubated GNRs were then used 
in biotin–streptavidin binding and blocking assays. For the binding assay, LGNRs-PSS-
PEG-Biotin and LGNRs-PSS-mPEG were incubated with streptavidin-coated polystyrene 
beads (3 µm diameter) and centrifuged for 10s at 1000g to separate beads from free GNRs. 
The same process was repeated in the blocking assay, except that the streptavidin-coated 
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beads were preincubated with excess free biotin to preclude specific binding of Large-
GNRs-PSS-PEG-Biotin. (b) Absorbance measurements of the supernatant from each of the 
four bead-GNR combinations were taken after incubation. The same concentration of GNRs 
(OD 1) was used in each incubation, but only the supernatants from the incubation of 
LGNRs-PSS-PEG-Biotin and streptavidin beads exhibited a significant decrease in GNR 
concentration. These results demonstrate the proof of principle that LGNRs-PSS can be 
functionalized with ligands that retain molecular binding specificity in the presence of 
nonspecific proteins, which will be advantageous for future applications to targeted 
molecular imaging. Photographs from these molecular specificity assays are presented in 
Figure S5.
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LGNRs are highly effective OCT contrast agents that enable single particle sensitivity in 
vitro and nanomolar sensitivity for noninvasive in vivo imaging. (a) Linear-scale OCT B-
scans of LGNRs and two concentrations of GNRs show that LGNRs scatter significantly 
more near-infrared light (~800 nm) than GNRs of equivalent plasmonic resonance per 
nanoparticle. LGNRs also display stronger scattering than GNRs even when LGNRs and 
GNRs are prepared to equal mass concentration (2 × 1010 nps/mL for LGNRs and 1.6 × 1011 
nps/mL for GNRs; the 8-fold increased GNR concentration accounts for the particle volume 
difference between LGNRs and GNRs). (b) Region of interest analysis shows that LGNRs 
exhibit ~4-fold greater scattering than GNRs prepared to equivalent mass concentration. 
Considering the 4-fold greater LGNRs signal as well as the 8-fold difference in particle 
concentrations, LGNRs can produce up to ~32-fold greater OCT contrast than GNRs per 
particle (*p < 0.0001). Yellow arrows indicate specular reflections from capillary tubes. 
Green arrows show examples of spherical impurities (d ~ 50 nm) present in GNR solutions. 
(c) LGNRs produce enough scattering to enable detection of individual LGNRs in water. 
When prepared to 500 fM, the number of LGNRs expected to be present within the imaged 
capillary volume is ~70. This number is roughly consistent with the number of discrete 
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puncta observed in the sample tube. The total signal increases for higher LGNR 
concentrations. Red arrows point to selected single LGNRs. (d) LGNRs-PSS-mPEG (250 µL 
of 23.5 nM) were tail vein-injected into a nude mouse bearing a U87MG tumor xenograft in 
the right ear pinna to achieve a particle concentration of 3 nM in circulation. OCT B-scans 
were acquired (completely noninvasively) before and after injection. LGNR-PSS-mPEG 
contrast results in increased OCT signal in blood vessels. LGNR-PSS-mPEG contrast-
enhancement reveals small blood vessels (red dashed circles) deep within the tumor that 
cannot be visualized prior to injection.
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